Sonnet BioTherapeutics Q1 EPS $(0.31) May Not Be Comparable To $(0.90) Estimate, Sales $18.63K Beat $18.00K Estimate
Sonnet BioTherapeutics Q1 EPS $(0.31) May Not Be Comparable To $(0.90) Estimate, Sales $18.63K Beat $18.00K Estimate
Sonnet BioTherapeutics第一季度每股收益美元（0.31美元）可能無法與預期的0.90美元（0.90美元）相提並論，銷售額爲18.63萬美元超過1.8萬美元的預期
Sonnet BioTherapeutics (NASDAQ:SONN) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.90) by 65.56 percent. This is a 98.24 percent increase over losses of $(17.60) per share from the same period last year. The company reported quarterly sales of $18.63 thousand which beat the analyst consensus estimate of $18.00 thousand by 3.48 percent. This is a 50.00 percent decrease over sales of $37.26 thousand the same period last year.
Sonnet BioTherapeutics（納斯達克股票代碼：SONN）公佈的季度虧損爲每股0.31美元，比分析師共識估計的0.90美元（0.90美元）高出65.56％。這比去年同期每股虧損17.60美元（17.60美元）增長了98.24％。該公司公佈的季度銷售額爲18,630美元，比分析師普遍預期的18,000美元高出3.48％。這比去年同期的37,260美元的銷售額下降了50.00％。